T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment - 12/05/18
, Neil Korman, MD b, William Abramovits, MD c, Scott T. Rottinghaus, MD d, Huaming Tan, PhD d, Annie Gardner, MS e, Geoffrey Mukwaya, MD f, Mandeep Kaur, MD g, Hernan Valdez, MD fAbstract |
Background |
Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor.
Objective |
To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients.
Methods |
Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell–dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses.
Results |
Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration.
Limitations |
There was no placebo control.
Conclusion |
Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell–dependent responses to PCV-13 and tetanus vaccines.
Le texte complet de cet article est disponible en PDF.Key words : immune response, Janus kinase inhibitor, pneumococcal vaccine, T cell, tetanus toxoid, tofacitinib
Abbreviations used : CI, ELISA, GMFR, JAK, LTE, OPA, PCV-13, RA, TEAE
Plan
| Drs Rottinghaus’ and Kaur's affiliations indicate their affiliation at the time of analysis. |
|
| Funding sources: Study and medical writing support sponsored by Pfizer Inc. |
|
| Conflicts of interest: Dr Winthrop has been a consultant and investigator for Pfizer Inc, AbbVie, Lilly, and Galapagos. Dr Korman has been an investigator, grant reviewer, and advisory board member for Pfizer Inc. Dr Abramovits has been a consultant, investigator, and advisor, and has participated in speakers bureaus for Pfizer Inc. Dr Valdez, Dr Tan, Ms Gardner, and Dr Mukwaya are shareholders and employees of Pfizer Inc. Dr Rottinghaus and Dr Kaur were employees and shareholders of Pfizer Inc at the time of this analysis. |
|
| Reprints not available from the authors. |
Vol 78 - N° 6
P. 1149 - juin 2018 Retour au numéro
Article précédent
- Association of very preterm birth with decreased risk of eczema: A systematic review and meta-analysis
- Tingting Zhu, Jing Zhao, Yi Qu, Li Zhang, Dezhi Mu
- Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial
- Zoe Diana Draelos, Michael H. Gold, Robert A. Weiss, Leslie Baumann, Steven K. Grekin, Deanne Mraz Robinson, Steven E. Kempers, Nancy Alvandi, Emily Weng, David R. Berk, Gurpreet Ahluwalia
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?